Published in Retina

The 2023 Retina Report

This is editorially independent content supported by advertising from Astellas
4 min read

We surveyed over 500 optometrists and ophthalmologists about the challenges they face diagnosing, treating, and managing retinal disease. Download your free copy of the report to read all about it!

The 2023 Retina Report
Retinal disease is one of the leading causes of vision impairment and blindness worldwide, with age-related macular degeneration accounting for an estimated 8 million cases around the globe.1 Diabetic retinopathy accounts for another 3.9 million cases and is reported to be a leading cause of vision impairment in middle-income countries, according to the World Health Organization (WHO).2
We ran this survey in August 2023 to better understand the main challenges facing eyecare practitioners (ECPs) today regarding the diagnosis, treatment, and management of various retinal diseases. We wanted to learn what roadblocks were presented by patients and practice workflows as well as look at the effects of the rapid advancements in the retina space. Additionally, we wanted to gauge the general awareness among practitioners of these latest advancements.
This version of the 2023 Retina Report is absolutely free to download, but space constraints have led us to spotlight broader industry metrics. For the full, comprehensive Pro Report complete with specific, in-depth data and insights, please contact our team at

Download the free version of the 2023 Retina Report, or keep reading for a sneak peek at the findings!


Keep reading for free!

Every article, ebook, and video is 100% free.

The 2023 Retina Report covers:

  • Confidence in diagnosis and treatment of retinal diseases
  • Common equipment brands
  • Innovation and the retina pipeline
  • And more!

Who’s who in the Retina Report

In response to our 2023 Retina Survey, we initially received a total of 724 responses—659 from optometrists and 65 from ophthalmologists. After a rigorous process of data cleaning and confirming the credibility of the respondents, we validated 513 responses for analysis.
This refined sample included 480 optometrists and 33 ophthalmologists, 99% of whom actively treated retinal disease. The data cleaning process helped us eliminate any outliers or questionable entries, ensuring that the insights and statistics you'll find in this report are both accurate and meaningful.

What retinal diagnostics do doctors have access to?

Among our respondents, 16% reported that their practice lacked ocular coherence tomography (OCT). Another 55% did not have OCT-angiography, a significant technological advancement in diagnostic imaging to identify certain nuances of retinal disease, such as AMD, macular holes, and choroidopathy, to name a few.

How confident are ECPs in diagnosing geographic atrophy?

When it comes to geographic atrophy (GA)—a growing concern among the ophthalmic community—respondents reported high confidence in both diagnosing and treating the condition, but nearly 75% described their knowledge of treatment options as “Intermediate” or lower.
There are a plethora of treatments for GA in the pipeline, as well as the commercially available SYFOVRE (pegcetacoplan injection) 15 mg/ 0.1 mL and IZERVAY (avacincaptad pegol intravitreal solution) 2 mg, two treatments that were approved by the FDA just this year.
That said, only 2% of respondents reported a high awareness of the retina treatment pipeline; 85% were “somewhat aware” or less.

How quickly are optometrists referring patients?

When asked about referral timelines for conditions requiring anti-VEGF treatment, ophthalmologists said that 32% were late or much too late.
This marks an area for further exploration into what factors contribute to this number and how optometrists and ophthalmologists could better collaborate to catch these patients earlier in the disease process.

Learn more about the state of retinal disease diagnosis and treatment by downloading the full report!

  1. GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the Global Burden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e144-e160. doi: 10.1016/S2214-109X(20)30489-7.
  2. World Health Organization. Blindness and vision impairment. World Health Organization. Published August 10, 2023. Accessed September 13, 2023.
Matt Geller, OD
About Matt Geller, OD

Matt Geller, OD is the co-founder and CEO of Eyes On Eyecare—the #1 provider of clinical and career education for the next generation of optometrists and ophthalmologists through our all-in-one digital content platform.

Matt Geller, OD
Michael S. Cooper, OD
About Michael S. Cooper, OD

Michael S. Cooper, OD is an Optometrist and Past Director of Professional Strategies at Kala Pharmaceuticals in Arlington, MA. He specializes in anterior segment disease where he has treated a variety of conditions including dry eye and lid diseases, allergy, and uveitis. He has produced research, participated on expert ocular surface disease round tables, and lectured domestically and internationally on topics such as corneal disease states, uveitis management, Lyme disease, emerging pathogens, sports-related eye injuries in children, and AMD pedigree relationships. Dr. Cooper is published in journals such as Review of Optometry, Modern Optometry, Cataract and Refractive Surgery Today, Clinical Ophthalmology, Optometry Times, Primary Care Optometry News, and Ophthalmology/Optometric Management. Additionally, he has collaborated with CollaborativeEYE and Eyetube on a variety of digital media segments including “Managing the Surgical Patient” and “Hot Topics”. He has been actively involved in global clinical studies for novel anti-infective therapeutics, evaluating the efficacy of meibomian gland treatment modalities, ocular surface diagnostic validation, and AMD genetic research. Recently, he was been awarded a federal grant to evaluate Diabetes care efficiency across a multispecialty environment in a community health center setting.

Michael S. Cooper, OD
Eyes On Eyecare Editorial Team
About Eyes On Eyecare Editorial Team

Led by Editor-in-Chief Eleanor Gold, PhD, Eyes On Eyecare is a digital publication that provides clinical and career education to the young generation of optometrists and ophthalmologists. We work with eyecare professionals to create compelling, educational content available for free to all those in the eyecare industry. To learn more about our team, values, and other projects, visit our About page.

Eyes On Eyecare Editorial Team
Eyes On Eyecare Site Sponsors
Astellas LogoOptilight by Lumenis Logo